If confirmed by additional studies in humans and clinically relevant animal models, advanced therapies to preserve regulated angiogenic responses, for example by delivering recombinant ANG-1 to restore endothelial cell quiescence, can be examined to determine if they offer clinical benefit as they have in other models of life-threatening infectious disease [42]. The gene discussed is ANGPT1; the disease is infectious disease.